On the 16th and 17th of February, we organized the second annual meeting of the European OA-BIO consortium in Davos, Switzerland.

Together with our OA-BIO partners Universiteit Utrecht , Chondrometrics GmbH, AO Research Institute Davos (ARI) and AO Foundation, we shared and discussed ongoing research on 4P004 (intra-articular liraglutide) as a potential disease-modifying osteoarthritis drug (DMOAD).

Discussions focused on the development of novel biomarkers and the ongoing phase 1 clinical trial.

‍

‍